Your AI-Trained Oncology Knowledge Connection!
Opinion
Video
Decentralization of Biomarker Testing: Expanding Access to Targeted Therapies and Clinical Trials in Underserved Populations
Author(s):
Panelists discuss how decentralizing biomarker testing improves access to targeted therapies and clinical trials for underserved populations by reducing geographic and systemic barriers, fostering equity in cutting-edge health care.
Video series above is prompted by the following:
- What are your thoughts on how decentralization of biomarker testing might address access to targeted therapies and clinical trials in underserved populations?
- Explore how testing decentralization can bridge gaps in access to cutting-edge treatments and clinical trials for marginalized or geographically distant populations.
Related Videos
Related Content
